Pharmaceutical marketing just got a shake-up. Solstice, a New York startup, raised $21 million in Series A funding to slash approval times for drug marketing materials.

The company targets a painfully slow process called MLR review—medical, legal, and regulatory checks that stall marketing assets for months. Solstice’s platform combines AI with in-house experts to compress this process from three months to under 48 hours.

Pharma companies spend over $100 billion on commercialization. Yet, their marketing workflows remain stuck in the last century: emails flying back and forth, multiple feedback versions, and no single system to manage it all. This creates bottlenecks that delay product launches and cost patients access to new treatments.

Solstice’s AI ingests clinical data, FDA documents, and approved literature to build marketing content grounded in evidence. Their proprietary models predict how likely each asset is to pass MLR before it even reaches human reviewers. This pre-vetting cuts down review rounds from an average 3.2 to 1.2 per asset.

Clients report launching campaigns 12 times faster and producing almost triple the content per quarter. The startup now works with over a dozen pharma firms, including top brands across oncology, immunology, and metabolic diseases.

Funding and Future Plans

The $21 million round was led by Transformation Capital with Twelve Below, Virtue Ventures, Ford Street Ventures, Go Global Ventures, and Cory Capital also investing. Total funding now sits near $25 million.

Solstice plans to expand its go-to-market strategy and scale product development. They’ll grow teams on both the product and customer sides to handle increased demand.

CEO Aris Saxena sums it up: “We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review, and performance insights in one AI-native system.”

Marketing directors echo the sentiment, praising the platform’s ability to cut back-and-forth delays and deliver personalized content at the pace modern brands require. This isn’t just about speed. It’s about smarter compliance and better engagement with doctors and patients.

Why It Matters

The pharma industry’s commercialization workflow hasn’t seen real innovation for decades. Solstice’s AI-native approach replaces clunky email chains with automated, evidence-backed content creation and review.

Faster marketing means drugs reach patients sooner during patent windows. It also means pharma companies can produce more targeted and effective campaigns without sacrificing compliance.

In a crowded, highly regulated market, that edge translates directly to saved time, reduced costs, and improved patient access. Solstice proves that AI can fix an industry bogged down by outdated processes—without cutting corners on safety or accuracy.